These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 17073629)

  • 1. Tenofovir plus didanosine as Nrti backbone in HIV-infected subjects.
    Bongiovanni M; Tordato F
    Curr Med Chem; 2006; 13(23):2789-93. PubMed ID: 17073629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunological effectiveness of the nucleoside/nucleotide analog combinations, tenofovir + lamivudine, didanosine + lamivudine and tenofovir + didanosine, in patients with HIV infection and sustained viral suppression].
    Cervero M; Torres R; Jusdado JJ; Rodríguez-Rosado R; Del Alamo M; García-Benaya E
    Enferm Infecc Microbiol Clin; 2006; 24(7):426-30. PubMed ID: 16956530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.
    Bongiovanni M; Gianotti N; Chiesa E; Nasta P; Cicconi P; Capetti A; di Biagio A; Matti A; Tirelli V; Marconi P; de Luca A; Mussini C; Gatti F; Zaccarelli M; Abeli C; Torti C; Antinori A; Castagna A; d'Arminio Monforte A
    Infection; 2007 Dec; 35(6):451-6. PubMed ID: 18034204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High virological failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir.
    Pérez-Elías MJ; Moreno S; Gutiérrez C; López D; Abraira V; Moreno A; Dronda F; Casado JL; Antela A; Rodríguez MA
    AIDS; 2005 Apr; 19(7):695-8. PubMed ID: 15821395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term safety and tolerability of didanosine combined with high- versus low-dose tenofovir disproxil fumarate in ambulatory HIV-1-infected persons.
    Young B; Weidle PJ; Baker RK; Armon C; Wood KC; Moorman AC; Holmberg SD;
    AIDS Patient Care STDS; 2006 Apr; 20(4):238-44. PubMed ID: 16623622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort.
    Balestre E; Dupon M; Capdepont S; Thiébaut R; Boucher S; Fleury H; Dabis F; Masquelier B;
    J Clin Virol; 2006 Jun; 36(2):95-9. PubMed ID: 16556509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine.
    Barrios A; Rendón A; Negredo E; Barreiro P; Garcia-Benayas T; Labarga P; Santos J; Domingo P; Sánchez-Conde M; Maida I; Martín-Carbonero L; Núñez M; Blanco F; Clotet B; Sambeat MA; Gil P; Gonzalez-Lahoz J; Cooper D; Soriano V
    AIDS; 2005 Mar; 19(6):569-75. PubMed ID: 15802975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load.
    Negredo E; Moltó J; Burger D; Viciana P; Ribera E; Paredes R; Juan M; Ruiz L; Puig J; Pruvost A; Grassi J; Masmitjà E; Clotet B
    AIDS; 2004 Feb; 18(3):459-63. PubMed ID: 15090798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinically stable treatment-experienced adults receiving tenofovir and didanosine.
    Di Biagio A; Beltrame A; Cenderello G; Ferrea G; De Maria A
    HIV Clin Trials; 2006; 7(1):10-5. PubMed ID: 16632460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir.
    Karrer U; Ledergerber B; Furrer H; Elzi L; Battegay M; Cavassini M; Gayet-Ageron A; Hirschel B; Schmid P; Russotti M; Weber R; Speck RF;
    AIDS; 2005 Nov; 19(17):1987-94. PubMed ID: 16260905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Checking up on ddI and tenofovir in people with HIV/AIDS.
    TreatmentUpdate; 2003; 15(3):4-5. PubMed ID: 17216846
    [No Abstract]   [Full Text] [Related]  

  • 14. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir.
    García-Benayas T; Rendón AL; Rodríguez-Novóa S; Barrios A; Maida I; Blanco F; Barreiro P; Rivas P; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2006 Apr; 22(4):333-7. PubMed ID: 16623636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir use in human immunodeficiency virus-1-infected children in the United kingdom and Ireland.
    Riordan A; Judd A; Boyd K; Cliff D; Doerholt K; Lyall H; Menson E; Butler K; Gibb D;
    Pediatr Infect Dis J; 2009 Mar; 28(3):204-9. PubMed ID: 19209091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical data I. Clinical experience with tenofovir in combination with nonnucleoside analogue transcriptase inhibitors].
    Bernardino de la Serna JI; Mora Rillo M; Arribas López JR
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():7-12. PubMed ID: 19195432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High rate of virological failure in maintenance antiretroviral therapy with didanosine and tenofovir.
    León A; Mallolas J; Martinez E; De Lazzari E; Pumarola T; Larrousse M; Milincovic A; Lonca M; Blanco JL; Laguno M; Biglia A; Gatell JM
    AIDS; 2005 Oct; 19(15):1695-7. PubMed ID: 16184042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily.
    Tung MY; Mandalia S; Bower M; Gazzard B; Nelson M
    HIV Med; 2005 May; 6(3):151-4. PubMed ID: 15876280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance.
    Ross L; Parkin N; Chappey C; Fisher R; Clair MS; Bates M; Tisdale M; Lanier ER
    AIDS; 2004 Aug; 18(12):1691-6. PubMed ID: 15280780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.